Pricing Log in Create free account
Friday 6 November 2026 Export HALO’s income statement to Excel — free account

Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.

Revenue
+39.2%
EPS
+45.6%
Free cash flow
−58.6%
Total debt
+115.1%

Quarter to September 2026, against a year earlier

104.29 18.67 −15.18%
Market cap
$14.0B
P/E
29.5×
Fwd P/E
17.9×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Halozyme Therapeutics, Inc. (HALO) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 23 added · 7 removed · 44 modified
P2I1A: no changes
8-K Nov 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 28, 2026 5.02 Departure or appointment of directors or officers Officer departure
8-K Sep 22, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 3.02 Unregistered sales of equity securities; 9.01 Financial statements and exhibits
8-K Sep 17, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 16, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 14, 2026 5.02 Departure or appointment of directors or officers
10-Q Jun 30, 2026 P1I2: 25 added · 6 removed · 26 modified
P2I1A: no comparison — the earlier filing's Item cannot be compared
8-K Aug 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 30, 2026 5.02 Departure or appointment of directors or officers
10-Q Mar 31, 2026
8-K May 11, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 5, 2026 5.07 Submission of matters to a vote of security holders
8-K Apr 30, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K Apr 22, 2026 5.03 Amendments to the articles or bylaws; change in fiscal year; 9.01 Financial statements and exhibits
8-K Mar 12, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 23 added · 13 removed · 47 modified
1A: 6 added · 26 modified
7: 46 added · 26 removed · 39 modified
8-K Feb 17, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 28, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 4, 2025 5.02 Departure or appointment of directors or officers
8-K Dec 4, 2025 5.02 Departure or appointment of directors or officers
8-K Nov 18, 2025 5.02 Departure or appointment of directors or officers
8-K Nov 6, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 3.02 Unregistered sales of equity securities; 9.01 Financial statements and exhibits
8-K Nov 6, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 5, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 3, 2025 2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K Oct 14, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Oct 1, 2025 5.02 Departure or appointment of directors or officers
8-K Sep 30, 2025 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Sep 30, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 18, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 8, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 31, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 20, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 17, 2024 2.02 Results of operations and financial condition
8-K Nov 6, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.